Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT06170489 Recruiting - Hodgkin Lymphoma Clinical Trials

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Start date: December 19, 2023
Phase: Phase 3
Study type: Interventional

The study is being conducted to compare JS004 plus Toripalimab with Investigator-Selected Chemotherapy in Patients with PD-(L)1 monoclonal antibody refractory Classic Hodgkin Lymphoma (cHL)

NCT ID: NCT06164327 Recruiting - Clinical trials for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Start date: December 1, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open Phase Ib clinical study to evaluate the safety,efficacy and pharmacokinetics of BEBT-908 combined with Rituximab (R) or combined with Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) or combined with Rituximab-Ifosfamide-Carboplatin-Etoposide (R-ICE) in the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).

NCT ID: NCT06164275 Recruiting - Clinical trials for Classic Hodgkin Lymphoma

Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma

Start date: February 6, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well giving pembrolizumab followed by chemotherapy with doxorubicin, vinblastine and dacarbazine works to treat patients with classical Hodgkin lymphoma. Pembrolizumab is a type of drug called a "monoclonal antibody (mAb)" that uses the body's immune system to help fight and kill cancer cells. Chemotherapy drugs, such as doxorubicin, vinblastine and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Giving pembrolizumab followed by chemotherapy may work to treat patients with classical Hodgkin lymphoma.

NCT ID: NCT06161896 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Characterization and Clinical Impact of the Gut Microbiota in Lymphoma

Start date: May 6, 2024
Phase:
Study type: Observational

The study is a prospective observational single-center cohort study which compare the gut microbiome of newly diagnosed Diffuse Large B-cell Lymphoma patients with the gut microbiome of healthy controls. Furthermore the impact of lymphoma treatment, immune phenotypes, cytokine profiles, metabolomics, inflammation, driver mutations, comorbidity, body composition and lifestyle on the microbiome is also investigated

NCT ID: NCT06160362 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Start date: October 31, 2023
Phase: N/A
Study type: Interventional

This is a study for patients who have been previously treated for NHL. The purpose of this study is to determine the safety and feasibility of double-target CART-19 and 20 cells to the patients with relapsed and refractory CD19+/CD20+ NHL.

NCT ID: NCT06158399 Recruiting - Clinical trials for DLBCL - Diffuse Large B Cell Lymphoma

AZA Combined With RCHOP in P53-mutated DLBCL.

Start date: November 22, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma

NCT ID: NCT06158386 Recruiting - Follicular Lymphoma Clinical Trials

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Start date: November 22, 2023
Phase: Phase 2
Study type: Interventional

To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.

NCT ID: NCT06156774 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Start date: April 18, 2024
Phase:
Study type: Observational

This is a multicenter prospective observational study lead by the FIL on sarcopenia and sGA as possible predictors of efficacy and toxicity outcomes in patients undergoing CAR-T cells treatment.

NCT ID: NCT06151730 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Start date: January 5, 2024
Phase:
Study type: Observational

This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.

NCT ID: NCT06151106 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Start date: November 22, 2023
Phase: Phase 2
Study type: Interventional

To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.